Eli Lilly Supply Agreement

Medpal AI PLC

28 January 2026

 

28 January 2026

MedPal AI plc

("MedPal AI" or the "Company")

Eli Lilly Supply Agreement

MedPal AI plc (AIM: MPAL), the AI-powered digital health company, is pleased to announce that MedPal Limited, its wholly owned subsidiary, has been approved as an authorised purchaser of Eli Lilly pharmaceutical products in the United Kingdom.

The approval enables the Company to purchase and dispense Eli Lilly's portfolio of medications, including Mounjaro® (tirzepatide), the GLP-1 receptor agonist approved for the treatment of type 2 diabetes and weight management.

Market Opportunity

Mounjaro is the UK's leading weight loss medication, commanding approximately 79% of the UK GLP-1 market and research indicates that approximately ten times more people in the UK purchase Mounjaro privately than receive it through the NHS, highlighting the substantial commercial opportunity in the private prescribing market. Alternative GLP-1 receptor Wegovy, which Medpal.clinic already supplies, represents 20% of the market. This approval means that it will now be able to offer GLP-1 patients their preferred medication.

The UK prescription weight loss medications market is forecast to grow from approximately £340 million in 2025 to £2 billion by 2033, driven by rising obesity prevalence and increasing adoption of GLP-1 therapies. An estimated 3.4 million people in the UK are eligible for tirzepatide treatment, with approximately 64% of adults in England classified as overweight or obese. Globally, the GLP-1 weight loss drugs market is projected to reach £120 billion by 2035. Direct supply access positions MedPal AI to serve the significant and growing private market demand through MedPal.clinic, where patients can access clinically supervised weight management pathways combining AI-powered triage with prescriber consultation.

Operational Capability

Medications will be dispensed from the Company's distribution centre in Swaffham, Norfolk, which utilises state-of-the-art robotic dispensing technology to ensure accuracy, efficiency and rapid fulfilment of patient orders. This automated infrastructure provides the scalability required to meet anticipated demand growth.

This development supports the Company's strategy to position MedPal.clinic as a leading digital platform for clinically supervised weight management services, combining AI-powered patient triage with access to innovative pharmaceutical treatments.

Jason Drummond, CEO of MedPal AI, commented:

"Securing direct supply rights with Eli Lilly, the manufacturer of the UK's leading weight loss medication, is an important milestone for MedPal AI. Access to Mounjaro strengthens our ability to serve patients through MedPal.clinic, where our AI triage technology connects individuals with appropriate clinical pathways for weight management. With our robotic dispensing facility in Swaffham, we are well positioned to meet growing patient demand."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END